NYSE · Healthcare
QIAGEN N.V. (QGEN)
As-reported financials and recent SEC filings for QIAGEN N.V., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.09B
Net income
$424.9M
Net margin
20.3%
Diluted EPS
$1.94
ROE
11.2%
P/E (TTM)
20.1×
Market cap
$8.13B
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Gross profit | $1.30B | $967.4M | $1.23B | $1.38B | $1.45B |
| Operating income | $465.9M | $97.7M | $409.9M | $531.5M | $630.1M |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| Diluted EPS | $1.94 | $0.37 | $1.48 | $1.84 | $2.21 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G/A2026-06-05
View on EDGAR →SD2026-06-01
View on EDGAR →6-K2026-05-08
View on EDGAR →6-K2026-05-08
View on EDGAR →6-K2026-05-01
View on EDGAR →IRANNOTICE2026-03-20
View on EDGAR →20-F2026-03-20
View on EDGAR →SCHEDULE 13G/A2026-02-10
View on EDGAR →Go deeper on QGEN
Search QIAGEN N.V.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.